CurrentCignaPolicy IP0023

Drug and Biologic Coverage Policy — Sedative‑hypnotic drugs for insomnia

Defines medical necessity and authorization criteria for a set of sedative-hypnotic prescription products used to treat insomnia for Cigna-administered health benefit plans; applies to providers requesting coverage for these drugs.

Policy Summary

PayerCigna

PolicySedative‑hypnotic drugs for insomnia

Policy CodePolicy IP0023

Change TypeAnnual revision — no criteria changes

Effective DateDec 15, 2024

Next Review Date

Key ActionObtain prior authorization with documentation that product-specific medical necessity criteria are met, including chronic insomnia diagnosis and required prior trials or behavioral therapy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

chronic insomniaprimary covered indication

≤12 moinitial authorization duration

≤12 moreauthorization duration

AASM 2017guideline cited

ACP 2016guideline cited

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Medical necessity criteria (generalized across listed sedative-hypnotics)

Covered when ALL of the following are met for the specific product:

Primary diagnosis: Diagnosis of chronic insomniaduration >3 months and frequency >=3 times/week

See disease overview for definition

Patient clinical status: Individual meets ONE of the following: has a cancer diagnosis OR meets ALL of the following: (1) age >=18 years; (2) has tried at least one form of behavioral therapy for insomnia (for example, relaxation training, stimulus control, sleep restriction); (3) not currently taking prescription stimulants (e.g., methylphenidate, amphetamine products); (4) underlying psychiatric and/or medical conditions that may cause or exacerbate insomnia have been evaluated and are being addressed

Applies across listed products per product-specific criteria

Product-specific prior therapy requirements: Documentation of prior trials, failure, contraindication, or intolerance to specified alternative agents or bioequivalent generics as required by the product (number and specific agents vary by product; examples include failure of generic zolpidem and failure of two or three listed alternatives)varies by product

See individual product criteria in policy (examples: failure of zolpidem generic plus two alternatives for some products; Quviviq/other agents may require three alternatives in certain age groups)

Any use of the listed sedative‑hypnotic products that is not specifically described in this policy is considered experimental, investigational, or unproven and may be denied.

The American Academy of Sleep Medicine guideline states that clinicians should not use trazodone, tiagabine, diphenhydramine, melatonin, tryptophan, or valerian to treat sleep onset or sleep maintenance insomnia.

Provider Responsibilities and Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for the sedative‑hypnotics listed in this policy. Providers must document that the member meets the medical necessity criteria specified for the requested product, including required trials of alternative agents or justification for exemptions (failure, contraindication, or intolerance) where step-therapy is indicated.

Applies to all listed formulations (e.g., zolpidem products, eszopiclone, zaleplon, doxepin/Silenor, suvorexant, daridorexant, lemborexant, and others referenced in Related Coverage Resources).
Prior authorization requests should include prior medication history and rationale for the requested agent.

Documentation Required

Clinical Documentation Expectations

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence‑based literature. Receipt of sample product does not satisfy criteria requirements for coverage.

Initial Authorization Requirements

Initial therapy criteria — Initial coverage requires meeting product-specific medical necessity criteria

Initial coverage requires meeting product-specific medical necessity criteria.

Initial approval: Meet the chronic insomnia definition AND meet the patient clinical status criteria (cancer diagnosis OR age >=18 with behavioral therapy tried, not taking prescription stimulants, and evaluation/addressing of underlying causes) AND satisfy product-specific prior trial requirements (e.g., failure/contraindication/intolerance to specified alternatives or bioequivalent generics)varies by product

Initial approvals may be granted for up to 12 months per product guidance

Behavioral therapy first — ACP recommendation for CBT-I as part of initial therapy considerations

Behavioral therapy is the recommended initial treatment for chronic insomnia; consider medication only after CBT-I is unsuccessful or per shared decision-making.

Behavioral therapy first:

Reauthorization / Continuation Criteria

Reauthorization criteria — Reauthorization requires ongoing documentation of benefit

Reauthorization requires ongoing documentation of benefit.

Reauthorization: Continuation is considered medically necessary when the initial medical necessity criteria continue to be met AND there is documentation of beneficial response to therapy

Reauthorization approvals may be granted for up to 12 months

Step Therapy Requirements

Requirement	Examples / agents
Prior trial requirement before coverage	Failure, contraindication, or intolerance to specified alternatives; number required varies by product and age group
Example — ages 18–64 (product-specific)	Failure of THREE of: Dayvigo (lemborexant), doxepin (Silenor generic), eszopiclone (Lunesta generic), ramelteon (Rozerem generic), zaleplon (Sonata generic), zolpidem (Ambien generic)
Example — age ≥65 (product-specific)	Failure, contraindication, or intolerance to ONE of listed alternatives (examples include temazepam [Restoril], doxepin, eszopiclone)
Product-specific exceptions — formulation allergy/inequivalence	For temazepam: trial of bioequivalent generic required unless formulation difference would cause significant allergy or serious adverse reaction

Shared decision-making element	Policy guidance
When to use shared decision-making	When CBT-I alone is unsuccessful and short-term medication use is being considered
Discussion topics to include	Benefits, harms, and costs of short-term pharmacologic therapy
Clinical recommendation strength	ACP: shared decision-making recommended (weak recommendation, low-quality evidence); CBT-I remains initial treatment (strong recommendation)

Site of Care Considerations

Billing Rule

Document and justify clinically appropriate site of care

Ensure the chosen site of care is reasonable and clinically appropriate for the patient and include evidence‑based justification in the record when applicable.

Site of care decisions should be supported by clinical rationale and evidence‑based literature as noted in the policy.

Background and Scope

Insomnia is characterized by difficulty initiating or maintaining sleep with associated daytime impairment. It is classified by duration as transient (<1 week), short‑term (≤3 months), or chronic (>3 months, typically occurring ≥3 times per week). Clinical guidelines emphasize that cognitive behavioral therapy for insomnia (CBT‑I) and other behavioral approaches (stimulus control, sleep restriction, relaxation) are the recommended initial treatments for chronic insomnia, with pharmacologic therapy considered when behavioral measures are unsuccessful or not appropriate.

Key Definitions

Chronic insomnia definition

DefinitionInsomnia lasting more than 3 months at a frequency of at least three times per week, with associated daytime consequences (e.g., daytime fatigue, irritability, decreased concentration)

Duration threshold> 3 months

Frequency thresholdAt least 3 times per week

Required impactAssociated daytime consequences (eg, fatigue, irritability, decreased concentration)

Behavioral therapy (CBT-I) — nonpharmacologic interventions

DefinitionNonpharmacologic interventions for insomnia including cognitive behavioral therapy for insomnia (CBT-I), stimulus control, sleep restriction, relaxation techniques, and related behavioral measures (eg, sleep hygiene and regular schedule)